Aprea Therapeutics 2025 Q3 Earnings Narrowed Net Loss of 21.4%

Aprea Therapeutics (APRE) reported fiscal 2025 Q3 results on Nov 12, 2025, with a 21.4% reduction in net loss year-over-year and guidance affirming cash runway into Q4 2026. The company’s performance aligns with expectations, highlighting progress in clinical programs despite ongoing financial challenges.

Revenue

Aprea Therapeutics’ total revenue plummeted by 99.5% to $1.85 million in 2025 Q3, down from $354.62 million in 2024 Q3. Grant revenue accounted for the entirety of Aprea’s total revenue, reflecting a stark decline in business activity.

Earnings/Net Income

The company narrowed its net loss to $2.97 million in 2025 Q3, a 21.4% improvement from the $3.78 million loss in 2024 Q3. Earnings per share (EPS) also improved, with a loss of $0.47 per share compared to $0.64 per share in the prior-year period. The reduction in per-share loss signals improved operational efficiency despite ongoing financial challenges.

Price Action

APRE shares declined 1.56% during the latest trading day, 3.96% over the past week, and 14.29% month-to-date, reflecting market uncertainty.

Post-Earnings Price Action Review

A strategy of purchasing APRE shares on quarterly earnings dates and holding for 30 days yielded a 24.2% return over three years, outperforming the market. This approach leveraged earnings releases as catalysts for price movements, with a 30-day holding period capturing short-term appreciation. The strategy demonstrated low volatility and consistent performance, underscoring the value of timing and disciplined investing in capitalizing on market reactions to earnings news.

CEO Commentary

Oren Gilad, Ph.D., highlighted clinical advancements in APR-1051 and ATRN-119. For APR-1051, three of four patients at 100 mg QD achieved stable disease in the ACESOT-1051 trial, with dose escalation advancing to 150 mg QD. ATRN-119’s recommended Phase 2 dose of 1,100 mg QD was confirmed, prompting strategic pauses in monotherapy enrollment to explore combination therapies. Gilad emphasized Aprea’s differentiated DDR approach and optimism for 2026 catalysts.

Guidance

Aprea reported $13.7 million in cash as of September 30, 2025, with a projected runway into Q4 2026. Q3 operating loss narrowed to $3.1 million from $4.1 million in Q3 2024, while R&D expenses totaled $1.6 million. The company plans to maintain operating expenses within cash reserves and advance clinical development, including combination strategies.

Additional News

Aprea Therapeutics disclosed clinical progress in its DDR programs and reaffirmed its cash runway. APR-1051 showed early disease control in biomarker-defined patients, with safety data primarily mild. ATRN-119’s Phase 2 dose confirmation shifted focus to combination trials with radiation and immunotherapy. The company also highlighted ongoing discussions to expand its pipeline through partnerships.